Botswana Blood Products Import Market -- HS Code 3002 Trade Data & Price Trend (Jan 2025)

Botswana Blood Products Import (HS 3002) Key Takeaways

Botswana’s Blood Products import under HS Code 3002 in January 2025 was dominated by veterinary vaccines, accounting for 76% of value, with high-value human medicine products as outliers. The market showed steady demand, with imports totaling 855.84K USD, likely influenced by healthcare needs and tariff adjustments. Supplier concentration was extreme, with one group controlling 98% of trade, creating supply chain risks. South Africa supplied 46% of imports by value, reflecting reliance on regional bulk shipments, while high-value finished products came from Europe. This analysis is based on cleanly processed Customs data from the yTrade database for January 2025.

Botswana Blood Products Import (HS 3002) Background

What is HS Code 3002?

HS Code 3002 covers human and animal blood products, vaccines, toxins, and cultures. These products are critical for healthcare, pharmaceuticals, and research industries, driving consistent global demand due to their essential role in medical treatments and disease prevention. Botswana's import of these products reflects their importance in supporting public health and veterinary services.

Current Context and Strategic Position

Under the 2025 trade agreement, Botswana applies annual tariff rate quotas for HS Code 3002 imports from MERCOSUR member states, as outlined in the [BURS tariff notes]. This policy underscores the need for careful monitoring of Botswana's blood products import volumes and costs. Given the country's reliance on these imports for healthcare infrastructure, fluctuations in trade terms or supply chains could significantly impact local availability. Tracking HS Code 3002 trade data is vital to ensure stable access and cost efficiency for Botswana's medical sector.

Botswana Blood Products Import (HS 3002) Price Trend

Key Observations

In January 2025, Botswana's imports of Blood Products under HS Code 3002 reached 855.84K USD, with a unit price of $61.25 per kg. This initial monthly figure sets a baseline for the year, reflecting steady procurement in the healthcare sector.

Price and Volume Dynamics

The January import levels for Blood Products may be influenced by recent regulatory changes, such as the implementation of annual tariff rate quotas for goods from MERCOSUR Member States, as detailed in the [BURS] schedule. This policy could affect cost structures and supply chains, aligning with typical industry patterns where medical imports remain prioritized despite external adjustments. The hs code 3002 value trend shows a solid start, potentially driven by ongoing healthcare demands and inventory management in Botswana's import framework.

Botswana Blood Products Import (HS 3002) HS Code Breakdown

Product Specialization and Concentration

In January 2025, Botswana's import under HS Code 3002 is heavily concentrated in veterinary vaccines, with the sub-code for vaccines for veterinary medicine dominating the market. According to yTrade data, this product accounted for over 76 percent of the total value and 73 percent of the weight, with a unit price of 64.03 USD per kilogram. High-priced items for human medicine, such as vaccines with unit prices exceeding 1200 USD per kilogram, are isolated anomalies and not part of the main analysis pool due to their extreme pricing.

Value-Chain Structure and Grade Analysis

The non-anomalous imports can be grouped into three categories: veterinary biologicals like vaccines, blood fractions including antisera, and other immunological products. Veterinary items form the bulk with moderate prices, while blood fractions and retail immunological products show higher unit prices, up to 697.71 USD per kilogram, indicating a mix of bulk and finished goods. This structure points to trade in differentiated manufactured products rather than fungible commodities, with value tied to specific applications and regulatory standards.

Strategic Implication and Pricing Power

For market players, the high-value human medicine segments offer significant pricing power but require strict compliance and quality control. The volume-driven veterinary market suggests competition on cost and scale. Strategic focus should prioritize investing in high-grade products and navigating import regulations for HS Code 3002 trade data in Botswana to capture value in specialized niches.

Table: Botswana HS Code 3002) Breakdown Details (Source: yTrade)

Check Detailed HS Code 3002 Breakdown

Botswana Blood Products Import (HS 3002) Origin Countries

Geographic Concentration and Dominant Role

South Africa is the dominant source for Botswana's Blood Products import in January 2025, holding 46.27% of the value share and 60.13% of the weight share. The weight share being higher than the value share points to imports of bulk or less processed blood products, such as plasma or raw materials for medical use. The high frequency share of 57.04% indicates regular, possibly weekly shipments, which is common for perishable medical supplies needing fresh delivery.

Origin Countries Clusters and Underlying Causes

The origin countries split into two main clusters based on trade patterns. South Africa and Tanzania form a volume cluster with high weight shares (60.13% and 32.20%, respectively), suggesting they supply bulk blood products, likely due to regional proximity and cost-effective logistics. Austria, Germany, Australia, and Switzerland make up a high-yield cluster with value shares exceeding weight shares (e.g., Austria's value share is 5.87% vs. weight share of 0.36%), indicating imports of specialized, high-value finished blood products like treated plasma or diagnostic kits, driven by advanced medical manufacturing in these countries.

Forward Strategy and Supply Chain Implications

Botswana's heavy reliance on South Africa for bulk blood products imports poses a supply chain risk, such as potential disruptions from regional issues. Diversifying sources among high-yield cluster countries could reduce dependency and ensure access to quality finished products. Strengthening logistics for perishable goods is key to maintaining steady supply.

Table: Botswana Blood Products (HS 3002) Top Origin Countries (Source: yTrade)

Get Complete Origin Countries Profile

Botswana Blood Products (HS 3002) Suppliers Analysis

Supplier Concentration and Dominance

According to yTrade data, Botswana's blood products import supplier market in January 2025 was highly concentrated. One group of suppliers handled nearly all the trade value, accounting for 97.91% of imports. This small set of Botswana blood products import suppliers also managed 98.77% of the total quantity, making them the clear market leaders.

Strategic Supplier Clusters and Trade Role

The profile of HS code 3002 suppliers indicates a direct-to-factory market structure. The dominant group includes companies like S A N B S and IRVENES AFRICA, which appear to be primary manufacturers or end-users rather than trading intermediaries. A secondary cluster of suppliers, including ONDERSTEPOORT BIOLOGICAL PRODUCTS and EMBRIO PLUS CC, was active but contributed minimally to total value, handling only 2.09% despite numerous shipments.

Sourcing Strategy and Vulnerability

Botswana's blood product supply chain relies heavily on a few key partners. This creates efficiency but also concentration risk. Diversifying the supplier base could mitigate potential disruptions. [BURS] notes that tariff rate quotas apply to certain imports, which may influence future sourcing decisions from alternative regions like MERCOSUR states.

Table: Botswana Blood Products (HS 3002) Top Suppliers List (Source: yTrade)

Check Full Blood Products Supplier lists

Action Plan for Blood Products Market Operation and Expansion

• Use hs code 3002 trade data to identify and contract with alternative suppliers from high-value clusters like Austria and Germany, reducing Botswana's Blood Products Import reliance on South Africa and mitigating supply chain disruption risks.
• Analyze shipment frequency data from hs code 3002 trade data to align inventory orders with actual delivery cycles, preventing overstock and ensuring fresh Blood Products supply chain management.
• Prioritize sourcing high-grade human medicine products by reviewing unit price trends in hs code 3002 trade data, capturing higher margins and enhancing competitiveness in Botswana's Blood Products Import market.
• Strengthen cold chain logistics by partnering with reliable carriers based on trade data insights, maintaining product integrity and reducing spoilage in the Blood Products supply chain.

Take Action Now —— Explore Botswana Blood Products Import Data

Frequently Asked Questions

Q1. What is driving the recent changes in Botswana Blood Products Import 2025 January?

The steady procurement of blood products in January 2025 reflects ongoing healthcare demands, with potential cost adjustments due to new tariff rate quotas for imports from MERCOSUR states.

Q2. Who are the main origin countries of Botswana Blood Products (HS Code 3002) 2025 January?

South Africa dominates with 46.27% of the value share, followed by Tanzania (32.20% weight share) and high-value suppliers like Austria (5.87% value share).

Q3. Why does the unit price differ across origin countries of Botswana Blood Products Import?

Price gaps stem from bulk veterinary vaccines (64.03 USD/kg) from South Africa versus high-value finished products like treated plasma (up to 697.71 USD/kg) from Austria and Germany.

Q4. What should importers in Botswana focus on when buying Blood Products?

Prioritize diversifying suppliers to mitigate reliance on South Africa, while investing in compliance for high-value human medicine segments.

Q5. What does this Botswana Blood Products import pattern mean for overseas suppliers?

Suppliers in high-yield countries (e.g., Austria, Germany) have opportunities to expand specialized exports, while bulk producers like South Africa face competition on cost.

Q6. How is Blood Products typically used in this trade flow?

Imports are primarily for veterinary vaccines (76% of value) and medical applications like blood fractions, reflecting demand for differentiated manufactured products.